Novelix Pharmaceuticals Limited, formerly known as Trimurthi Limited, recently announced a strategic collaboration with GMBU e.V. of Halle (Saale), Germany to facilitate the technology transfer and scale-up production of Astaxanthin at its research and manufacturing facilities in Hyderabad. This partnership involves the transfer of proprietary technology and expertise from GMBU e.V. a reputable German non-profit research organization specializing in biotechnology and environmental technologies, to enable Novelix to cultivate and produce the primary sources of Astaxanthin on a commercial scale. 

Novelix will invest in infrastructure, including establishing a GMP-certified production facility at its Techno Park site, to manufacture Astaxanthin in bulk targeting markets in Europe, North America, and India.GMBU e.V. founded in 1992, is a leading research institution that bridges the gap between academic research and industrial application, specializing in biotechnology, bioanalytics, chemical and bioprocess engineering and nanotechnology. 

The partnership between Novelix and GMBU e.V. is seen as a milestone that represents a strong Indo-German collaboration in biotechnology and life sciences, with the shared goal of delivering affordable, high-quality therapeutic and nutraceutical products. The agreement marks a critical step in scaling up the production of bioactive compounds such as Astaxanthin. This is not only a technological transfer but a move towards commercial viability, indicating the growing importance and demand for natural antioxidants in global health markets. 

The scale-up capability will enable Novelix to compete on an international level while addressing local market needs. GMBU e.V.’s proprietary technology for cultivating the raw materials needed provides Novelix with a unique advantage. Dr. Enrico Ehrhardt, Head of the Department of Molecular Biology, GMBU e.V described this as a “significant milestone”  for development scaling up purposes and that the collaboration would open new avenues for joint innovation across biotechnology and healthcare domains.

Gattu Gyan Prakash, Director, Novelix Pharmaceuticals Limited stated that beyond product development, the partnership symbolized a robust Indo-German collaboration model in biotechnology and life sciences. This collaboration illustrates the convergence of research, technology, and strategic infrastructure development, positioning both organizations at the forefront of innovation in biotechnology and nutraceutical markets.